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Bladder cancer is among the most prevalent malignancies, and is characterised by frequent tumour recurrences and localised
inflammation, which may promote tissue invasion and metastasis. Microarray analysis was used to compare gene expression in normal
bladder urothelium with that in tumours at different stages of progression. The innate immune response gene, interferon-stimulated
gene 15kDa (ISG15, GIP2), was highly expressed at all stages of bladder cancer as compared to normal urothelium. Western blotting
revealed a tumour-associated expression of ISG15 protein. ISG15 exhibited a stage-associated expression, with significantly (Po0.05)
higher levels of ISG15 protein in muscle-invasive T2–T4 tumours, compared with normal urothelium. Although ISG15 is involved in
the primary immune response, ISG15 expression did not correlate with bladder inflammation. However, immunohistochemical
staining revealed expression of ISG15 protein in both cancer cells and stromal immune cells. Interestingly, a significant fraction of
ISG15 protein was localised to the nuclei of tumour cells, whereas no nuclear ISG15 staining was observed in ISG15-positive stromal
cells. Taken together, our findings identify ISG15 as a novel component of bladder cancer-associated gene expression.
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Bladder cancer in the US is ranked the fourth most prevalent
cancer type among men (6%) and tenth among females (2%), and
similar figures are found in the rest of the industrialised world
(Jemal et al, 2003). The average survival rate 1 year after diagnosis
is 81%, 66% after 5 years, and 57% after 10 years. If bladder cancer
is diagnosed at an early stage in development when the tumour is
confined to the bladder, the 5-yearsurvival rate is 94%; however, if
the malignancy is not detected until it has spread regionally
beyond the bladder or as distal metastases, the survival rate drops
to 48 and 6%, respectively (The American Cancer Society, 2003).
Recurrence is a particular risk in bladder cancer as tumours are
frequently accompanied by precancerous genetic alterations in the
surrounding, morphologically normal urothelium (Rao et al, 1993;
Hartmann et al, 1999; Czerniak et al, 2000). Bladder tumours
classified as benign mucosal (Ta) and submucosal invasive (T1)
comprise 80% of initial patient diagnoses; the remaining 20% of
patients present T2–T4 tumours that eventually develop distal
metastases (Dyrskjot, 2003). Invasion of bladder tumour cells into
the submucosa is accompanied by a marked host immune
response; the resultant localised cell killing is thought to further
promote tumour spread. The host immune system plays an
important role in tumour detection and eradication (Dunn et al,
2004). Similar to the response to foreign agents, phagocytic and
antigen presenting cells of the innate immune system function to
detect endogenous malignantly transformed cells. An innate
immune response is initiated through the direct contact of
immune cells with malignant cells, or via activation of Toll-like
receptors by tumour-derived molecules, and results in the
transcriptional induction of immune response genes. Consistent
with this scenario, recent studies have determined that molecular
components of the innate immune response are critical for host
antitumour activity (Shankaran et al, 2001; Akazawa et al, 2004;
Zheng et al, 2004), and that exogenous activators of innate
immunity are efficacious antitumour agents in an adjuvant therapy
setting (Krieg, 2004).
Interferon-stimulated gene 15kDa (ISG15) is a interferon-
inducible ubiquitin-like protein and its expression is highly
induced upon viral or bacterial infection (Loeb and Haas, 1992;
Kim and Zhang, 2003). Type I interferons (IFNs) induce several
hundred IFN-stimulated genes, including ISG15, through the Janus
kinase/signal transducer and activator of transcription (Jak/STAT)
signalling pathway. Interferon alpha and beta are the strongest
inducers of the ISG15 gene (Der et al, 1998). The ISG15 protein is
comprised of tandem ubiquitin homology domains (Haas et al,
1987; Potter et al, 1999) with distinct intracellular and extracellular
activities. Within cells, ISG15 is covalently conjugated to cellular
proteins in an enzymatic pathway similar to that used by ubiquitin.
In contrast to ubiquitin, post-translational modification by ISG15
does not result in the proteasome-dependent degradation of ISG15
conjugates. Multiple target proteins of ISG15 have recently been
identified; however, the biological consequences of modification
by ISG15 remain to be determined (Hamerman et al, 2002;
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sMalakhov et al, 2003; Giannakopoulos et al, 2005; Zhao et al,
2005). Extracellular ISG15 is proposed to have a cytokine-like
function by activating CD3þ T cells (D’Cunha et al, 1996a,b).
Most recently, ISG15 was identified in a screen of red blood cell
lysates for neutrophil chemotactic factors, suggesting a novel role
for extracellular ISG15 (Owhashi et al, 2003).
In an effort to identify changes in gene expression associated
with bladder cancer, microarray analysis was used to compare the
mRNA profile in normal bladder urothelium with that in tumours
from different stages of progression. We focused on immune
response genes to investigate their relationship to bladder cancer-
associated inflammation. The ISG15 gene was significantly
upregulated in bladder tumours as compared to normal tissues,
and ISG15 protein increased with advancing stage of the bladder
cancer. Importantly, ISG15 expression did not correlate with a
generalised inflammatory response, suggesting that it is specifi-
cally associated with bladder tumours. Indeed, immunohistochem-
ical staining showed ISG15 expression in both cancer cells and
stromal immune cells. Our findings indicate that elevated
expression of ISG15 is a novel feature of bladder cancer.
MATERIALS AND METHODS
Tissue material
In total, 138 bladder tumours and 27 normal urothelium biopsies
from healthy individuals were obtained by surgery and frozen
immediately in a preserving solution of guanidinium thiocyanate
and stored at  801C. Informed consent was obtained in all cases,
and protocols were approved by the local scientific ethical
committee (Internal Review Board).
DNA microarray analysis
Preparation of labelled cRNA, microarray hybridisation, washing,
and scanning was performed according to the manufacturer’s
instructions as described previously (Dyrskjot et al, 2003). Two
types of expression microarrays were used in the study, affymetrix
HG-U133A microarrays and customised affymetrix microarrays
(EOS Hu03) designed by EOS Biotechnology Inc. (now PDL
BioPharma, Fremont, CA, USA). A single EOS Hu03 microarray
contains 459000 probesets, which represent approximately 45000
genes/ESTs, as well as 6900 ab initio predicted genes not
represented in human genome sequences at the time of chip
design (Eaves et al, 2002).
Immunohistochemistry
For immunohistochemical staining, either 5-mm paraffin-em-
bedded tissue sections or bladder tissue microarrays were used.
Bladder tissue microarrays contained normal urothelium (N¼10),
Ta tumour (N¼20), and T2–T4 tumour (N¼20). The tissue
sections were deparaffinised, rehydrated, boiled in a microwave
oven for 5min, allowed to cool at room temperature for 20min,
and then incubated in methanol/H2O2 (100ml methanolþ1.5ml
(wv
 1)H 2O2) for 10min to block endogenous peroxidase. The
tissue sections were then incubated in TEG buffer (Tris-EGTA,
pH 9.0) boiled for 10min in a microwave, allowed to cool at room
temperature for 20min, and incubated with Pronase DAKO S2013
(DakoCytomation A/S, Glostrup, Denmark) for 20min at room
temperature. Then, tissue sections were incubated with rabbit
polyclonal anti-ISG15 antibody (30mgml
 1) and visualised using
the Envisiont visualisation system. As chromogen, we used
DABþ from DAKO (K3868; DakoCytomation A/S, Glostrup,
Denmark), and counterstained with Mayer’s haematoxylin and
mounted in Aquatex
s (1.08562; Merck, Darmstadt, Germany). The
evaluation of the tissue microarrays was performed independently
by two individuals (MAJ, LDA). The ISG15 expression was scored
as being present or not. Nuclear staining of urothelial and cancer
cells was scored positive when more than 50% of the nuclei were
ISG15 positive. Unspecific tissue border staining was excluded
from the analysis.
Western blot analysis
Tissue lysates were prepared using radioimmunoprecipitation
assay buffer (150mM sodium chloride, 1.0% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 50mM
Tris, pH 8.0; Upstate, Charlottesville, VA, USA). The protein
concentration in the lysates were determined by the Bradford
microassay (Bio-Rad, Hercules, CA, USA), and 10-100mg of lysate
protein was separated on 12% SDS–polyacrylamide gel electro-
phoreses gel for analysis of ISG15 protein and ISG15 conjugates.
Proteins were electrotransferred to Immobilon-P membrane
(Millipore, Billerica, CA, USA). The membranes were blocked in
5% nonfat milk TBST buffer (10mM Tris, pH 8.0, 150mM NaCl,
0.1% vv
 1 Tween 20) for 1h at room temperature and then
sequentially reacted to the primary antibody (mouse monoclonal
anti-ISG15 antibody) for 1h in blocking buffer and the horseradish
peroxidase-conjugated secondary antibody (1:10000 dilution;
Sigma-Aldrich, St Louis, MO, USA). The immunoreactive complex
was visualised by the Pierce SuperSignal chemiluminescent
substrate (Pierce, Rockford, IL, USA) and exposure to X-Omat
AR film (Kodak, Rochester, MN, USA).
Bioinformatics
Microarray data for ISG15 expression profiling was either
normalised using the RMA procedure (Bolstad et al, 2003) (HG-
U133A) or by procedures previously described in Dyrskjot et al
(2005) (Eos Hu03 microarray). Two independent samples sets were
analysed by either affymetrix HG-U133A arrays (N¼54; nine
normal urothelium and 45 Ta tumours) or custom affymetrix
arrays (N¼111 Eos Hu03 microarrays; 18 normal urothelium, 28
Ta tumour, 20 T1 tumours, and 45 T2–T4 tumours). Pairwise
comparisons of levels of ISG15 protein expression between
normal and tumour samples were performed using Student’s
t-test. Pearson’s correlation coefficients (r) were calculated in
Microsoft Excel and P¼0.001 levels of significance were calculated
for both data sets using the formula: R¼(U 1)/(Uþ1), where




, Z(0.001)¼3.09, N¼54, or N¼111. Only
genes with median expression of more than 50 were included in
the analysis.
RESULTS
ISG15 gene transcript is increased in bladder cancer
We performed a gene expression profiling analysis using micro-
arrays and determined that the ISG15 transcript was associated
with bladder cancer. Comparison of ISG15 gene expression in
nine normal urothelium samples and 45 Ta tumours revealed a
2.7-fold increase in ISG15 transcript expression in Ta tumours
(P¼1.31E 05) (Figure 1A). To validate this finding, and to extend
the study to also include samples from invasive tumours, the ISG15
gene expression profiling analysis was repeated on an independent
sample set consisting of 18 normal urothelium samples, 28 Ta,
20 T1, and 45 T2–T4 tumours (Figure 1B). These samples were
analysed using custom Affymetrix arrays (Eos Hu03 microarray).
In agreement with the first microarray study, the ISG15 transcript
was increased in Ta tumours (1.4-fold, P¼5.00E 05), in T1
tumours (1.7-fold, P¼4.14E-08), and to the greatest extent in
T2–T4 tumours (2.0-fold, P¼4.12E-13) compared to normal
bladder. The median expression of ISG15 transcripts increased
in 93% (26 out of 28) of the Ta tumours, 100% (20 out of 20)
of the T1 tumours, and 98% (44 out of 45) of the T2–T4 compared
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sto the median expression of the 18 normal tissue samples. ISG15
has been implicated in the primary immune response to infection
by microbial pathogens; however, we did not find any correlation
between increased expression of ISG15 and inflammation of the
bladder (Student’s t-test, P40.1). The level of inflammation was
determined by two independent methods: pathological examina-
tions of random bladder biopsies, and testing for bacterial
infections using the urine Multistix
s 7 test (Bayer A/S Diagnostics
Kgs. Lngby, Denmark), which measures the nitrite and leucocyte
levels (Robertson and Duff, 1988). These findings suggested that
increased ISG15 expression is associated with bladder cancer
rather than an associated immune response.
ISG15 protein expression
Microarray analysis measures the level of mRNA, however, protein
expression may be a more accurate measure of cellular function,
and does not always mirror mRNA expression. To determine if the
bladder cancer-associated increase in ISG15 mRNA corresponded
to an increase in ISG15 protein expression, tissue biopsies from 25
patients diagnosed with different stages of bladder cancer and 10
normal individuals were analysed by Western blotting. ISG15
expression was quantified by densitometric analysis, and the
values were normalised to the constitutively expressed beta-actin
protein. The Western blotting analysis revealed consistently
increased levels of ISG15 protein in bladder cancer compared to
normal samples (Po0.05) (Figure 2A and Table 1). Importantly, a
comparison of ISG15 expression across different stages of bladder
tumours revealed a significant increase in ISG15 protein level with
advancing tumour stage. The ISG15 protein levels increased 4.1-
fold in Ta and T1 tumours, and as much as a 12.1-fold increase in
T2–T4 tumours (Table 1). Only a single 15kDa protein band
representing unconjugated ISG15 protein was observed in Western
blots (see Figure 2B), and high molecular weight bands represent-
ing ISG15-modified cellular proteins were not observed (not
shown). These results indicate that ISG15 protein expression is
significantly increased in individuals diagnosed with bladder
cancer, and suggest that ISG15 is most highly expressed in muscle
invasive disease.
The analyses described in Figures 1 and 2A utilised normal
tissue obtained from individuals with no history of bladder cancer,
and thus may reflect the variation in basal ISG15 expression in the
population at large. To compare ISG15 expression in normal
bladder and bladder tumour samples that have an identical genetic
background, biopsies were obtained from the tumour and from an
adjacent, histologically normal, region of the same bladder from 29
patients with late stages of bladder cancer (T2–T4). Western blot
analysis of these samples revealed that, similar to the comparison
of ISG15 expression in normal individuals and cancer patients,
unconjugated ISG15 was increased in tumour as compared to
normal urothelium from the same patient. A representative
Western blot analysis of five patients is shown in Figure 2B.










































Normal Ta tumour T1 tumour T2–T4 tumour
A
B
Figure 1 Microarray analysis of ISG15 gene expression in normal
urothelium and bladder tumour. (A) ISG15 gene expression in normal
urothelium (n¼9) and in tumours from patients with Ta grade bladder
tumours (n¼45) (HG-U133A). (B) ISG15 gene expression in normal
urothelium (n¼18), Ta tumours (n¼28), T1 tumours (n¼20), and T2–
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Figure 2 (A) Densitometric analysis of ISG15 protein expression by
Western blotting analysis. The relative expression of each tumour group
compared to the normal level is shown in the diagram (All T¼all tumours).
All ISG15 levels are normalised to actin expression. (B) Western blotting
analysis of ISG15 protein expression in 10 paired samples; T2–T4 tumour
(T) and normal bladder (N) from the same cancer patient (upper panel).
The actin protein expression was measured as a control for equivalent
protein loading (lower panel).




Normal (n¼10) 1.070.25 —
Ta (n¼15) 4.170.06 Po0.05
T1 (n¼5) 4.170.05 Po0.05
T2–T4 (n¼5) 12.170.02 Po0.05
All tumours (n¼25) 5.770.04 Po0.05
ISG15¼interferon-stimulated gene 15kDa; s.d.¼standard deviation; Ta¼benign
mucosal tumours; T1¼submucosal invasive tumours; T2–T4¼tumours with distal
metastases.
aNormalised means of ISG15 protein expression determined by
densitometry analysis of Western blotting (normal¼1).
bPairwise comparisons
between the normal group and each tumour group using Student’s t-test.
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sImmunohistochemical analysis of ISG15 expression
Tumour biopsies contain a heterogeneous mixture of cells
including tumour, endothelial, and immune cells; therefore, gene
expression in these samples represents the sum of contributions
from distinct cell types. In order to characterise the ISG15
expression pattern in normal urothelium and bladder tumours,
we performed a series of immunohistochemical stainings. ISG15
expression was evaluated by staining paraffin-embedded tissue
sections with specific polyclonal antibody raised against ISG15
protein in rabbit. In total, ISG15 expression was analysed in both
complete biopsy samples (four Ta, and five T2–T4 tumours), and
in tissue microarray samples (20 Ta, and 20 T2–T4 tumours). To
evaluate the ISG15 expression under normal conditions, 10 normal
urothelium samples were stained with ISG15 antibody; these
samples were also included in the tissue microarray. The antibody
was tested for specificity for ISG15 by Western blotting analysis
(Supplementary Figure 1), and it only recognised one protein band
identical to ISG15 protein with the expected molecular weight of
approximately 15kDa.
Staining of bladder tumour sections with antibody specific to
ISG15 revealed specific signal for ISG15 in both cancer cells and
stromal immune cells (Figures 3 and 4). As negative controls,
either slides without primary antibody or stained with rabbit null
serum were included; both methods resulted in no staining, as
expected (Figures 3 and 4). Figure 4 shows a tumour-infiltrating
blood vessel that contains several strongly ISG15-positive immune
cells. The exact lineage of those immune cells remains to be
determined. The two tumours shown in Figure 3 mirror our
previous findings that T2–T4 tumours express more ISG15 protein
than Ta tumours as seen by Western blotting analysis. Compared
to normal urothelium, significantly more tumours display ISG15
expression, as 100% (18 out of 18) of the T2–T4 and 89% (17 out
of 19) of the Ta tumours stained positive for ISG15 protein (w
2-test,
Po0.05). Only 38% (three out of eight) normal urothelium
samples were positive (Figure 5A). A significant change in the
staining pattern of stromal cells was not observed when we
compared normal urothelium with tumours, indicating that ISG15
expression in this cell type is not associated with bladder cancer.
Supplementary Figure 2 shows normal urothelium, Ta, and T2–T4
tumours stained with ISG15 antibody. Interestingly, our analysis
revealed that not only did the fraction of samples staining positive





Figure 3 Immunohistochemical staining of ISG15 expression in bladder
tumours. Tissue material obtained from two patients; 1518-1 (Ta tumour)
and 1014-1 (T2–T4 tumour). Original magnification:  20.
Rabbit poly-ISG15 ab Control (null serum)
Ta
795-13
Figure 4 A tumour-infiltrating blood vessel with ISG15-positive immune
cells. Tissue material obtained from patient 795-13 with a Ta tumour.












































































ISG15 protein expression A
B
C
Figure 5 (A) Immunohistochemical analysis of ISG15 expression using
tissue microarray normal urothelium: N¼10; Ta tumours: N¼20; T2–T4
tumours: N¼20. (B) Distribution of samples with ISG15-positive nuclei
(450%) among normal urothelium samples, Ta tumours, and T2–T4
tumours. (C) Nuclear ISG15 expression of a Ta tumour. Original
magnification:  40.
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sfor ISG15 increase in tumours, but the subcellular staining pattern
also differed in tumour as compared to normal urothelium. A
significant number of the tumours displayed nuclear staining by
ISG15 (63% Ta tumours, and 39% T2–T4 tumours), whereas this
phenomenon was not seen in normal urothelium (w
2-test, Po0.05)
(Figure 5B).
ISG15 gene correlation analysis
Inflammation of the bladder wall is frequently observed in bladder
cancer patients. In this study, 64% of the patients were found
positive for local inflammation by pathological examination of
random bladder biopsies. Interferons are proinflammatory cyto-
kines that induce high levels of ISG15 expression; therefore, we
sought to determine if bladder cancer-associated ISG15 expression
may originate from a general response to IFN-mediated inflam-
mation. To do this, a correlation analysis was performed to search
for genes that correlated with ISG15 gene expression based on the
microarray data previously generated. The ISG15 gene was found
to correlate strongly with a group of IFN-inducible immune-
related genes. Only genes having correlation coefficients higher
than 0.410 were considered significant (Po0.001, N¼54, HG-
U133A microarrays). For further information see Materials and
Methods. A subset of the significantly correlated genes is shown in
Table 2. In order to validate this finding, the correlation
coefficients to the ISG15 gene in the validation data set generated
by the custom affymetrix microarray (N¼111, EOS Hu03
microarrays) were measured. All of the genes shown in Table 2
were repeatedly found to correlate with ISG15 in these indepen-
dent samples. As a control, the probeset for the beta-actin gene was
included, and it did not show a significant correlation to ISG15 as
expected. To extend the analysis, the expression of known pro- and
anti-inflammatory genes were examined; however, none of those
genes showed a significant positive correlation to ISG15. These
findings suggest that ISG15 dysregulation in bladder cancer does
not appear to reflect a generalised inflammatory response as
changes in pro- and anti-inflammatory markers between normal
and tumour samples are insignificant.
DISCUSSION
We have performed microarray analysis in combination with
Western blotting and immunohistochemical staining to study
ISG15 expression in a large population of bladder cancer patients.
Interferon-stimulated gene 15kDa was differentially expressed in
normal urothelium and bladder tumours, as it exhibited significant
upregulation in early-stage tumours, and displayed a further
increase in expression, which correlated with progression to a
muscle invasive T2–T4 stage. This pattern of expression was
observed in analyses using two independent microarray platforms,
indicating that ISG15 expression is strongly associated with
bladder cancer. Previously identified bladder cancer markers have
been of limited utility in clinical applications owing to the variable
(HRAS; Fitzgerald et al, 1995) or low (o20%; CCND1; Hovey et al
(1998); and ERBB2; Bringuier et al (1996) frequency of altered
expression or activity in tumours. CDC91L1 was recently identified
as an oncogene that is overexpressed in 430% of bladder cancer
cell lines and primary tumours, making it one of the most
commonly altered oncogenes found in bladder cancers (Guo et al,
2004). In comparison, we found the ISG15 protein upregulated in
nearly all of the tumours analysed in the study; it was over-
expressed in 93% (26 out of 28) of Ta tumours, 100% (20 out of 20)
of T1 tumours, and 98% (44 out of 45) of T2–T4 compared to the
normal tissue samples.
In good agreement with the microarray results, the level of
ISG15 protein was also increased in tumours. The levels
of expression were highly stage-associated, as ISG15 protein










Interferon, alpha-inducible protein (clone IFI-15K) GIP2 1.00 1.00 Type 1-2
Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse) MX1 0.33 0.84 Type 1-2
Hypothetical protein FLJ20035 FLJ20035 0.82 0.68 n.d
Proteasome (prosome, macropain) activator subunit 2 (PA23 beta) PSME2 0.81 0.73 Type 2
Myxovirus (influenza virus) resistance 2 (mouse) MX2 0.79 0.61 Type 1-2
Interferon regulatory factor 7 IRF7 0.79 0.65 Type l
Hypothetical protein FU22693 FLJ22693 0.79 0.71 n.d
Caspase-1, apoptosis-related cysteine protease (interleukin-1. beta, convertase) CASP1 0.78 0.43 Type 2
Interferon-induced protein with tetratrico peptide repeats 1 IFIT1 0.76 0.56 Type l
20-50-Oligoadeny(late synthetase 3, 100kDa OAS3 0.76 0.75 Type1-2
Interferon-induced protein with tetratricopeptide repeats 4 IFIT4 0.76 0.67 Type l
Major histocompatibility complex, class 1, F HLA-F 0.76 0.42 Type 2
Indoleamine-pyrrole 2,3 dioxygenase INDO 0.75 0.37 Type 2
Proinflammatory genes
Interleukin-1, beta IL1B 0.40
# 0.07
#
Interleukin-1, alpha IL1A 0.01
# 0.23
#
Interleukin-6 (interferon, beta 2) ILG 0.13
# 0.38




Interleukin-13 IL13  0.42  0.09
#




Actin, beta ACTS 0.27
# 0.24
#
IFN¼interferon; IL¼interleukin;TGF¼transforming growth factor.
yCalculated Pearson’s correlation coefficients (r) of significantly ISGlS-correlating genes (Po0.00l). The levels
of significance are P40.41 (HG-U133AJ, and P40.29 (EOS Hu03). Genes that do not significantly correlate with ISG1S are marked by #. The ACTS gene is shown as a control.
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sincreased through the tumour stages Ta, T1, to T2–T4. The mean
levels in T2–T4 tumours were increased approximately 12-fold
compared to normal tissue. A general increase in ISG15 protein in
individual cancer cells of late-stage tumours, and the presence of
considerably more ISG15-positive stromal immune cells in late
stage as compared to Ta tumours was observed by immunohisto-
chemical staining, and both of these factors likely contributed to
the large increase in ISG15 expression.
Interferon-stimulated gene 15kDa is normally expressed at low,
basal levels in the absence of a specific inducer; therefore, we
examined the microarray data for signalling components and
effector genes that may reveal the gene induction pathway
responsible for enhanced ISG15 expression in bladder tumours.
Interferon expression was not detected in the bladder tumour
samples analysed; however, a Pearson correlation analysis revealed
that ISG15 expression was significantly correlated with a group of
IFN-induced genes involved in the immune response. Moreover,
the expression of several pro- and anti-inflammatory genes was
unchanged between normal and bladder tumour tissue, and did
not correlate with ISG15 expression. In agreement with this
analysis, we did not find any correlation between ISG15 expression
and inflammation in the patients in the study. Thus, despite its
established role as a primary immune response gene, the ISG15
expression in bladder cancer appears to be independent of
associated bladder inflammation (Loeb and Haas, 1992; Kim and
Zhang, 2003). These findings suggest that ISG15 and the subset of
correlating inflammation mediators may represent a specific host
response to bladder cancer, rather than a generalised inflammatory
response.
Staining of bladder tumour sections and paired normal and
tumour samples obtained from the same bladder cancer patient
with antibody specific to ISG15 protein revealed a specific
expression of ISG15 protein in cancer cells. Other cells types,
such as stromal immune cells, did also stain positive for ISG15.
These cells may arise from the many blood vessels present in the
tumour tissue; in support of this prediction, ISG15-positive cells
were observed within tumour-infiltrating blood vessels. Interest-
ingly, a significant fraction of ISG15 protein was localised to the
nuclei of cancer cells, whereas ISG15 protein exhibited a diffuse
cytoplasmic staining pattern in ISG15-positive stromal cells. This
compartmentalisation of ISG15 may reflect tumour-associated
nuclear functions of ISG15 or the presence of ISGylated cellular
proteins in the nucleus. Indeed, several nuclear proteins are
modified by ISG15 (Giannakopoulos et al, 2005; Zhao et al, 2005).
The mechanistic basis and functional consequences of nuclear
ISG15 require further study.
The tissue microarray analysis of ISG15 expression revealed that
the fraction of ISG15-positive samples was increased in the groups
of Ta and T2–T4 tumours compared to normal urothelium. One
hundred per cent of T2–T4 tumours stained positive for ISG15,
whereas only approximately 40% of the normal samples stained for
ISG15. These findings demonstrate a strong correlation between
enhanced ISG15 expression and bladder cancer. Further studies
are required to evaluate the prognostic and diagnostic potential of
ISG15 and to address the potential role of ISG15 in the malignant
phenotype.
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